Patents by Inventor Christopher J. Dinsmore

Christopher J. Dinsmore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Insulin-Like Growth Factor-1 Receptor Inhibitors
    Publication number: 20150119394
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating Insulin-Like-Growth Factor I Receptor and Insulin Receptor. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 30, 2015
    Inventors: Abhijit Roychowdhury, Rajiv Sharma, Malcolm Mascarenhas, Chandrika B-Rao, Shashikant M. Patil, Sambhaji Chavan, Nitin Lad, Smriti Khanna, Christopher J. Dinsmore
  • Bicyclic diamines as janus kinase inhibitors
    Patent number: 8937077
    Abstract: The instant invention provides compounds of formula I which are Jak inhibitors, and as such are useful for the treatment of Jak-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: January 20, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: David Joseph Guerin, Jason D. Brubaker, Michelle Martinez, Joon O. Jung, Neville J. Anthony, Mark E. Scott, Carolyn Michele Cammarano, Dawn Marie Mampreian Hoffman, Hyun Chong Woo, Christopher J. Dinsmore, Philip Jones
  • Insulin-Like Growth Factor-1 Receptor Inhibitors
    Publication number: 20140045832
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating Insulin-Like-Growth Factor I Receptor and Insulin Receptor. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Application
    Filed: April 19, 2012
    Publication date: February 13, 2014
    Applicants: PIRAMAL ENTERPRISES LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Sarala Balachandran, Christopher J. Dinsmore, Abhijit Roychowdhury, Rajiv Sharma, Ram Asrey Vishwakarma
  • BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS
    Publication number: 20130225577
    Abstract: The instant invention provides compounds of formula I which are Jak inhibitors, and as such are useful for the treatment of Jak-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Application
    Filed: October 17, 2011
    Publication date: August 29, 2013
    Inventors: David Joseph Guerin, Jason D. Brubaker, Michelle Martinez, Joon O. Jung, Neville J. Anthony, Mark E. Scott, Carolyn Michele Cammarano, Dawn Marie Mampreian Hoffman, Hyun Chong Woo, Christopher J. Dinsmore, Philip Jones
  • Tyrosine kinase inhibitors
    Patent number: 8222269
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives of formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: July 17, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Matthew H. Katcher, Alan B. Northrup
  • Tyrosine kinase inhibitors
    Patent number: 8101603
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: January 24, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Matthew H. Katcher, Alan B. Northrup
  • Tyrosine kinase inhibitors
    Patent number: 8008295
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: August 30, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Douglas C. Beshore, Jeffrey M. Bergman, Craig W. Lindsley
  • Potassium channel inhibitors
    Patent number: 7879839
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: February 1, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman, Douglas C. Beshore, B. Wesley Trotter, Kausik K. Nanda, Richard Isaacs, Linda S. Payne, Lou Anne Neilson, Zhicai Wu, Mark T. Bilodeau, Peter J. Manley, Adrienne E. Balitza
  • Quinoline potassium channel inhibitors
    Patent number: 7825131
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: November 2, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman
  • Isoquinolinone potassium channel inhibitors
    Patent number: 7781457
    Abstract: The present invention relates to compounds having the structure formula (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: August 24, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Richard Isaacs, Christopher J. Dinsmore, Charles J. McIntyre, Linda S. Payne, David A. Claremon
  • Isoquinoline potassium channel inhibitors
    Patent number: 7763614
    Abstract: The present invention relates to compounds of structural formula I: I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: July 27, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Richard Isaacs, Christopher J. Dinsmore, B. Wesley Trotter, Nigel Liverton, Douglas C. Beshore, Nathan R. Kett, Charles J. McIntyre, Kausik K. Nanda, David A. Claremon
  • Isoquinolinone potassium channel inhibitors
    Patent number: 7741322
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: June 22, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman, Charles J. McIntyre, Richard Isaacs, David A. Claremon
  • Isoquinolinone potassium channel inhibitors
    Patent number: 7709476
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: May 4, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman, Charles J. McIntyre, David A. Claremon
  • Isoquinoline potassium channel inhibitors
    Patent number: 7691879
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: April 6, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: B. Wesley Trotter, Kausik K. Nanda, Nathan R. Kett, Christopher J. Dinsmore, Gerald S. Ponticello, David A. Claremon
  • Quinoline potassium channel inhibitors
    Patent number: 7692017
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: April 6, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman
  • TYROSINE KINASE INHIBITORS
    Publication number: 20100041652
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Application
    Filed: October 26, 2009
    Publication date: February 18, 2010
    Inventors: Christopher J. Dinsmore, Douglas C. Beshore, Jeffrey M. Bergman, Craig W. Lindsley
  • Tyrosine Kinase Inhibitors
    Publication number: 20090291941
    Abstract: The present invention relates to pyrido[3,2-c]benzazocinone derivatives and related compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: October 18, 2006
    Publication date: November 26, 2009
    Inventors: Christopher J. Dinsmore, Jongwon Lim, Alan B. Northrup
  • Tyrosine kinase inhibitors
    Publication number: 20090203684
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives of formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: July 6, 2007
    Publication date: August 13, 2009
    Inventors: Christopher J. Dinsmore, Matthew H. Katcher, Alan B. Northrup
  • Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
    Publication number: 20090197908
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: June 22, 2006
    Publication date: August 6, 2009
    Inventors: Christopher J. Dinsmore, Ana Esther Gabarda Ortega, David J. Guerin, James P. Jewell, Jason D. Katz, Jongwon Lim, Michelle R. Machacek, Ryan D. Otte, Jonathan R. Young
  • Potassium channel inhibitors
    Patent number: 7569589
    Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: August 4, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Christopher J. Dinsmore, Jeffrey M. Bergman, B. Wesley Trotter, Lou Anne Neilson, Zhicai Wu, Peter Manley, John Hartnett